Interview with Interview with Elizabeth C. Verna

Interview with Kim Olthoff

Interview with Parsia Vagefi

Liver allograft biopsy is crucial to the posttransplant management of patients treated for end-stage chronic liver disease, ALF, or HCC. Markers of graft injury such as parenchymal and biliary injury can be useful, but aren't specific, and enzyme changes may lack sensitivity in the context of transplantation.

HCV infection universally recurs in patients who are viremic at the time of transplantation, leading to reduced graft survival and increased patient mortality. Review the current interferon-based therapies and learn about emerging drugs and interferon-free treatment from experts Dr. Asmeen Bhatt and Dr. Gregory Everson.

Acute liver failure (ALF) manifests in patients without preexisting liver disease or cirrhosis, and the results can be devastating. Most patients quickly become critically ill, and approximately one third of ALF patients won't survive without liver transplantation. Read expert commentary from Dr. Oren Fix on the etiology, risks, and prognosis, to better manage patients with ALF.

Liver transplant recipients generally need lifelong immunosuppression - approximately 7 to 17 per cent of patients experience an episode of acute cellular rejection with 3 to 12 months of LT, respectively.

ince the first liver transplant operation in 1963, the field has experienced huge medical and surgical advances. Drs. Miller and Diago Uso review the complex interplay of donor and recipient factors which now contribute to 5-year survival rates approaching 75 per cent.

Successful treatment of HCV improves survival after liver transplantation, but antiviral therapy for patients awaiting transplantation or on immunosuppression after LT continues to be clinically challenging. In this era of rapidly changing HCV therapy, Dr. Elizabeth Verna explains strategies for eliminating hepatitis C in pre- and post-LT settings.

HBV was once regarded as a contraindication for liver transplantation. In the last 20 years advances such as HBIG and LAM have made HBV infection one of the best indications for LT, although cost and availability of prophylactic therapies can be challenges.